ABSTRACT
The immunomodulatory effect of hyperbaric oxygen, involving altered cytokine release by macrophages, is well described. Importantly, however, it is not known what the relative contribution is of the hyperbaric environment of the cells vs. increased oxygen tension on these hyperbaric oxygen-dependent effects. We compared, therefore, cytokine release by murine macrophages under hyperbaric oxygen, hyperpressure of normal air and normobaric conditions. We observed that hyperbaric oxygen enhanced cytokine release of both unstimulated as well as lipopolysaccharide (LPS)-challenged macrophages. Hyperpressure of normal air, however, enhanced LPS-induced cytokine production but did not elicit cytokine release in unstimulated macrophages. To further investigate the molecular details underlying the effects of hyperbaric oxygen, we investigated the effect of the p42/p44 mitogen-activated protein (MAP) kinase inhibitor PD98059 and the p38 MAP kinase inhibitor SB203580. Neither inhibitor, however, had a significant effect on the modulatory effects of hyperbaric oxygen on cytokine release. We concluded that the immunomodulatory effect of hyperbaric oxygen contains a component for which hyperpressure is sufficient and a component that apart from hyperpressure also requires hyperoxygenation.
Subject(s)
Hyperbaric Oxygenation , Macrophages/drug effects , Macrophages/immunology , Oxygen/pharmacology , Animals , Cells, Cultured , Dimethyl Sulfoxide/pharmacology , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Imidazoles/pharmacology , Lipopolysaccharides/pharmacology , Macrophages/enzymology , Macrophages/metabolism , Mice , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Pyridines/pharmacology , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein KinasesABSTRACT
PURPOSE: Hypoxic tumor cells are an important factor of radioresistance. Hyperbaric oxygen (HBO) and normobaric carbogen (95% oxygen, 5% carbon dioxide) increase the oxygen delivery to tumors. This study was performed to explore changes of tumor oxygenation during a course of fractionated irradiation and to determine the effectiveness of normobaric carbogen and HBO during the final phase of the radiation treatment. METHODS AND MATERIALS: Experiments were performed on the rhabdomyosarcoma R1H growing on WAG/Rij rats. After 20 X-ray fractions of 2 Gy within 4 weeks, oxygen partial pressure (pO2) was measured using the Eppendorf oxygen electrode under ambient conditions, with normobaric carbogen or HBO at a pressure of 240 kPa. Following the 4-week radiation course, a top-up dose of 10-50 Gy was applied in 2-10 fractions of 5 Gy with or without hyperoxygenation. RESULTS: HBO but not carbogen significantly increased the median pO2 in irradiated tumors. The radiation doses to control 50% of tumors were 38.0 Gy, 29.5 Gy, and 25.0 Gy for air, carbogen, and HBO, respectively. Both high oxygen content gas inspirations led to significantly improved tumor responses with oxygen enhancement ratios (OERs) of 1.3 for normobaric carbogen and 1.5 for HBO (air vs. carbogen: p = 0.044; air vs. HBO: p = 0.02; carbogen vs. HBO: p = 0.048). CONCLUSION: Both normobaric carbogen and HBO significantly improved the radiation response of R1H tumors. HBO appeared to be more effective than normobaric carbogen, both with regard to tumor oxygenation and response to irradiation.
Subject(s)
Carbon Dioxide/therapeutic use , Hyperbaric Oxygenation , Oxygen/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Rhabdomyosarcoma/radiotherapy , Animals , Dose Fractionation, Radiation , Oxygen/metabolism , Partial Pressure , Radiobiology , Radiotherapy Dosage , Rats , Rhabdomyosarcoma/blood supplySubject(s)
Oxygen/metabolism , Blood Gas Analysis/history , Blood Gas Analysis/methods , Blood Gas Monitoring, Transcutaneous , Capillary Permeability/physiology , History, 17th Century , History, 20th Century , Humans , Hyperbaric Oxygenation , Oxygen/therapeutic use , Partial Pressure , PolarographyABSTRACT
In this paper we report the effects of Hyperbaric Oxygen (HBO) exposure on the uptake and retention of meta-Iodobenzylguanidine (MIBG) in human platelets and two neuroendocrine cell lines. The combination of [131I] MIBG and HBO is used for therapy of neuroblastoma. Exposure to HBO can cause oxidative stress, which is potentially capable of affecting uptake and storage of MIBG in both neuroendocrine cells and platelets. Oxidative stress generated by menadione decreased both the uptake and retention of MIBG in the platelets and the cell lines. HBO did not affect these processes, indicating that the HBO induced oxidative stress is not high enough to affect the MIBG uptake and storage pathways in these cells. This suggests that the positive effects observed by the treatment of neuroblastoma patients with the combination of HBO and [131I] MIBG are most likely not due to improved uptake or retention of MIBG in the neuroblastoma. Neither can reduced cytotoxicity (trombocytopenia) be expected due to decreased uptake/retention of [131I] MIBG in platelets or their precursor cells.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Blood Platelets/metabolism , Hyperbaric Oxygenation , Iodobenzenes/pharmacokinetics , Neuroblastoma/metabolism , PC12 Cells/metabolism , 3-Iodobenzylguanidine , Animals , Humans , Imipramine/pharmacology , Oxidative Stress , Rats , Tumor Cells, CulturedSubject(s)
Blood Gas Monitoring, Transcutaneous , Hyperbaric Oxygenation , Adolescent , Adult , Aged , Aged, 80 and over , Blood Gas Monitoring, Transcutaneous/statistics & numerical data , Child , Child, Preschool , Evaluation Studies as Topic , Humans , Linear Models , Middle Aged , Oxygen/blood , Wound HealingSubject(s)
Antineoplastic Agents/therapeutic use , Hyperbaric Oxygenation , Iodobenzenes/therapeutic use , Neuroblastoma/therapy , 3-Iodobenzylguanidine , Child , Female , Follow-Up Studies , Humans , Male , Neoplasm Recurrence, Local , Neuroblastoma/drug therapy , Neuroblastoma/mortality , Survival Rate , Time FactorsABSTRACT
The high risk group of patients with neuroblastoma are children over 1 year with stage IV disease. Most series report a maximum of 20% survival at 5 years. For recurrent neuroblastoma stage IV, cure rates are not reported in the literature, but they are nil. Any treatment for recurrent neuroblastoma stage IV remains a therapeutic dilemma. The outcome of radiation therapy is variable. A very important factor in tumour treatment remains tumour hypoxia, and others, such as metabolic factors, also play a role. Combined application of radiation modifiers may influence the final survival rate. In an attempt to improve the survival of recurrent neuroblastoma stage IV, hyperbaric oxygen and radioionated meta-Iodobenzylguanidine (MIBG) was used in a clinical setting. Although survival may not be used as a determinant of the usefulness of a treatment for stage IV neuroblastoma disease, a better one is not available. In this study, at 28 months, a cumulative probability of survival of 32% was recorded for patients treated with [131I]MIBG and hyperbaric oxygen compared to 12% for [131I]MIBG treatment alone. These preliminary results are promising but further studies are needed to reveal substantial therapeutic gain.
Subject(s)
Hyperbaric Oxygenation , Iodine Radioisotopes/therapeutic use , Iodobenzenes/therapeutic use , Neuroblastoma/radiotherapy , Radiation Tolerance , 3-Iodobenzylguanidine , Adolescent , Adult , Child , Child, Preschool , Humans , Infant , Neoplasm Recurrence, Local , Neoplasm Staging , Neuroblastoma/pathology , Survival RateABSTRACT
Microcirculatory hemodynamics of the skin during hyperbaric oxygenation were assessed by determination of nailfold capillary red blood cell velocity (Vrbc). Under hyperbaric conditions a continuous increase in Vrbc was found. Control values, 0.43 +/- 0.12 mm. sec-1 (mean +/- sem), were significantly (P < 0.05) lower compared with Vrbc at the end of hyperbaric oxygenation (0.62 +/- 0.16 mm.sec-1).
Subject(s)
Erythrocytes/physiology , Hyperbaric Oxygenation , Skin/blood supply , Adult , Blood Flow Velocity/physiology , Capillaries/physiology , Female , Humans , Male , Nails/blood supply , Skin Temperature/physiologySubject(s)
Hyperbaric Oxygenation , Lung , Muscles/metabolism , Oxygen Consumption , Pulmonary Alveolar Proteinosis/metabolism , Pulmonary Alveolar Proteinosis/therapy , Therapeutic Irrigation , Female , Humans , Lung/physiopathology , Male , Middle Aged , Oxygen/blood , Partial Pressure , Pulmonary Alveolar Proteinosis/bloodABSTRACT
In the present study skeletal muscle PO2 measurements were performed in patients with gas gangrene and anaerobic soft tissue infections before, during and after hyperbaric oxygen therapy. Polarographic PO2 needle electrodes appeared to be suitable for application during different ambient pressures. We found that patients with gas gangrene revealed higher skeletal muscle PO2 values than patients with an anaerobic soft tissue infection. This may be explained by a higher metabolic rate within the anaerobically infected soft tissues. The higher PO2 values in gas gangrene may be caused by alpha toxins, affecting cellular and intracellular membranes thus destroying PO2 diffusion barriers.